Article Dans Une Revue Immunotherapy Année : 2024

Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives

Résumé

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatment of HNSCCs, mainly in combination with standard chemotherapy. This review focuses on the results of the main phase III studies evaluating ICIs in recurrent or metastatic HNSCCs. The efficacy and indications according to the PD-L1 status, the main predictive biomarker, are discussed. The results of trials assessing ICI efficacy for locally advanced disease, including the neoadjuvant setting are also discussed. Finally, therapeutic combinations that are potential treatments for HNSCCs, including ICIs and targeted therapies such as anti-EGFR agents, are presented.
Fichier non déposé

Dates et versions

hal-04833198 , version 1 (12-12-2024)

Identifiants

Citer

Amaury Daste, Mathieu Larroquette, Nyere Gibson, Matthieu Lasserre, Charlotte Domblides. Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives. Immunotherapy, 2024, 16 (3), pp.187--197. ⟨10.2217/imt-2023-0174⟩. ⟨hal-04833198⟩

Collections

CNRS
2 Consultations
0 Téléchargements

Altmetric

Partager

More